Tags

Type your tag names separated by a space and hit enter

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Int J Infect Dis. 2012 Aug; 16(8):e597-602.IJ

Abstract

BACKGROUND

The recommended standard therapeutic regimen for chronic hepatitis patients with hepatitis C virus (HCV) genotype 3 is pegylated interferon plus ribavirin for 24 weeks. The aim of the present study was to evaluate treatment efficacy and variables predictive of treatment success, interactions among variables contributing to a response to therapy, and the utility of the rapid virological response (RVR; week 4 virological response) to predict treatment outcomes in HCV genotype 3-infected patients in routine clinical practice.

METHODS

We prospectively studied baseline and during-treatment factors associated with a sustained virological response (SVR) in HCV genotype 3-infected patients who received pegylated interferon alfa-2a (PEG-IFN α2a) 180 μg/week plus ribavirin 800 mg daily for 24 weeks and who were followed for 24 weeks after the completion of treatment.

RESULTS

Four hundred and twenty-six treated patients were included in the analysis; 320 (75.1%) showed an SVR. The following factors were assessed for their ability to predict SVR by means of univariable and multivariable logistic regression analysis: patient age, sex, pre-treatment viral load, pre-treatment alanine aminotransferase (ALT), body mass index (BMI), and RVR. Four factors - age, pre-treatment viral load, pre-treatment ALT, and RVR - were statistically significant predictors of SVR (p<0.05) in the univariable analysis. Factors showing a significant association with SVR were assessed by multivariable logistic regression analysis. In the multivariable analysis, independent factors associated with SVR were the attainment of RVR (odds ratio (OR) 11, 95% confidence interval (CI) 6.15-20.69; p<0.0001), patient age ≤40 years (OR 4.2, 95% CI 2.30-7.96, p<0.0001), and a low pre-treatment viral load (≤8 × 10(5) IU/ml; OR 3.4, 95% CI 1.87-6.25; p<0.0001). The effect of RVR in patients aged >40 years was more pronounced than in those aged ≤40 years: 81.1% of patients aged >40 years who achieved an RVR had an SVR, whereas only 7.5% of patients aged >40 years who did not achieve an RVR had an SVR (p<0.05).

CONCLUSIONS

RVR is an independent variable that is predictive of SVR. Moreover older patients (>40 years) who achieve an RVR are likely to have an SVR, while patients who do not achieve an RVR and who have a high pre-treatment viral load (>8 × 10(5) IU/ml) are unlikely to have an SVR.

Authors+Show Affiliations

Diagnostic Department, Nuclear Medicine Oncology and Radiotherapy Institute, Hanna Road, Islamabad, 44000 Pakistan. hafsa.aziz@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22658873

Citation

Aziz, Hafsa, et al. "Analysis of Variables and Interactions Among Variables Associated With a Sustained Virological Response to Pegylated Interferon Alfa-2a Plus Ribavirin in Hepatitis C Virus Genotype 3-infected Patients." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 16, no. 8, 2012, pp. e597-602.
Aziz H, Raza A, Waheed Y, et al. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Int J Infect Dis. 2012;16(8):e597-602.
Aziz, H., Raza, A., Waheed, Y., Gill, U., & Gill, M. L. (2012). Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 16(8), e597-602. https://doi.org/10.1016/j.ijid.2012.03.012
Aziz H, et al. Analysis of Variables and Interactions Among Variables Associated With a Sustained Virological Response to Pegylated Interferon Alfa-2a Plus Ribavirin in Hepatitis C Virus Genotype 3-infected Patients. Int J Infect Dis. 2012;16(8):e597-602. PubMed PMID: 22658873.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. AU - Aziz,Hafsa, AU - Raza,Abida, AU - Waheed,Yasir, AU - Gill,Uzma, AU - Gill,Muzaffar Lateef, Y1 - 2012/06/01/ PY - 2012/01/11/received PY - 2012/03/17/revised PY - 2012/03/23/accepted PY - 2012/6/5/entrez PY - 2012/6/5/pubmed PY - 2013/4/17/medline SP - e597 EP - 602 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int. J. Infect. Dis. VL - 16 IS - 8 N2 - BACKGROUND: The recommended standard therapeutic regimen for chronic hepatitis patients with hepatitis C virus (HCV) genotype 3 is pegylated interferon plus ribavirin for 24 weeks. The aim of the present study was to evaluate treatment efficacy and variables predictive of treatment success, interactions among variables contributing to a response to therapy, and the utility of the rapid virological response (RVR; week 4 virological response) to predict treatment outcomes in HCV genotype 3-infected patients in routine clinical practice. METHODS: We prospectively studied baseline and during-treatment factors associated with a sustained virological response (SVR) in HCV genotype 3-infected patients who received pegylated interferon alfa-2a (PEG-IFN α2a) 180 μg/week plus ribavirin 800 mg daily for 24 weeks and who were followed for 24 weeks after the completion of treatment. RESULTS: Four hundred and twenty-six treated patients were included in the analysis; 320 (75.1%) showed an SVR. The following factors were assessed for their ability to predict SVR by means of univariable and multivariable logistic regression analysis: patient age, sex, pre-treatment viral load, pre-treatment alanine aminotransferase (ALT), body mass index (BMI), and RVR. Four factors - age, pre-treatment viral load, pre-treatment ALT, and RVR - were statistically significant predictors of SVR (p<0.05) in the univariable analysis. Factors showing a significant association with SVR were assessed by multivariable logistic regression analysis. In the multivariable analysis, independent factors associated with SVR were the attainment of RVR (odds ratio (OR) 11, 95% confidence interval (CI) 6.15-20.69; p<0.0001), patient age ≤40 years (OR 4.2, 95% CI 2.30-7.96, p<0.0001), and a low pre-treatment viral load (≤8 × 10(5) IU/ml; OR 3.4, 95% CI 1.87-6.25; p<0.0001). The effect of RVR in patients aged >40 years was more pronounced than in those aged ≤40 years: 81.1% of patients aged >40 years who achieved an RVR had an SVR, whereas only 7.5% of patients aged >40 years who did not achieve an RVR had an SVR (p<0.05). CONCLUSIONS: RVR is an independent variable that is predictive of SVR. Moreover older patients (>40 years) who achieve an RVR are likely to have an SVR, while patients who do not achieve an RVR and who have a high pre-treatment viral load (>8 × 10(5) IU/ml) are unlikely to have an SVR. SN - 1878-3511 UR - https://www.unboundmedicine.com/medline/citation/22658873/Analysis_of_variables_and_interactions_among_variables_associated_with_a_sustained_virological_response_to_pegylated_interferon_alfa_2a_plus_ribavirin_in_hepatitis_C_virus_genotype_3_infected_patients_ L2 - http://linkinghub.elsevier.com/retrieve/pii/S1201-9712(12)00127-0 DB - PRIME DP - Unbound Medicine ER -